Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

A retrospective analysis of hospital discharge records forS. pneumoniaediseases in the elderly population of Florence, Italy, 2010–2012

“…22 In 2006, Merito et al estimated an overall incidence rate for pneumonia among the elderly population of 16.3 per 100 000 persons. 23 Moreover, IPD and risk of death is higher in patients with co-morbidities. Patients with certain conditions are associated with an increased risk of contracting, and dying from IPD.…”

Cost-effectiveness analysis of pneumococcal polysaccharide vaccination from age 60 in São Paulo State, Brazil

“…The mean value of this range was used for the base case: 21% ( Table 2). In addition, as reported in various publications, 11,24,37,38,41,42,53,54,56,62,63 a 10% waning rate each year was applied and a total duration of effectiveness was fixed conservatively at 5 years ( Table 2).…”

“…This analysis was conducted in Sao Paulo State, diseases, vaccination with PPV23 is again more cost-effective or cost-saving compared to no vaccination strategy among the elderly, considering only direct medical costs. [24][25][26][27] This economic benefit increases with age of elderly targeted and vaccination of all individuals above the age 65 years is comparable in terms of cost-effectiveness to many accepted health care interventions. 27 The study's limitations were related to the various inputs used.…”

Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination at risk adults and elderly in Turkey

“…Nevertheless, data found in patient's file were more precise in 2006 than previous year following hospital recommendations which can explain the higher cost but also increase the robustness of these costs. In comparison of IPD costs of several western European countries, 15,20 the costs of illness found in our retrospective study are higher. However, they are similar to US cost data.…”